Last reviewed · How we verify
NCT05228106
68Ga-PSMA-617 PET/CT for PSMA-expressing Tumor: a Pragmatic Study
trial testing [68Ga]-PSMA-617 in Solid Cancers in 1,000 participants. Currently enrolling.
31 January 2027
Quick facts
| Lead sponsor | Centre de recherche du Centre hospitalier universitaire de Sherbrooke |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 21 January 2022 |
| Primary completion | 31 January 2027 |
| Estimated completion | 31 January 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- [68Ga]-PSMA-617
Conditions studied
- Solid Cancers — all drugs for Solid Cancers →
Sponsor
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Who can join
Eligibility, any sex, with Solid Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project aims to monitor the innocuity/safety profile of cyclotron-produced \[68Ga\]-PSMA-617 PET imaging in PSMA-expressing cancers. It is a single-site, pragmatic, non-randomized and open-label study, with no control group. Although prostate cancers constitute the usual recommended population for this PET modality, recent evidences suggest that most solid tumors express substantial amount of PSMA in their neovasculature. As such, all cancers (excluding non-solid cancers) will be eligible for \[68Ga\]-PSMA-617 PET imaging in this trial, for as long as their tumors express PSMA. This study also aims to instigate the use of \[68Ga\]-PSMA-617 in the routine standard-of-care for detection and follow-up of eligible cancers. FInally, this project seeks to gather information about the impact on patient management this novel PET modality will have over the current standard-of-care.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pathways and challenges in the clinical translational of radiopharmaceuticals for pediatric investigations.
Stauff E, Karimi H, Kecskemethy HH, Shaffer TH, et al · · 2025 · PMID 41282032 · DOI 10.3389/fmed.2025.1658588
Verify or expand the search:
- PubMed search for NCT05228106
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Cancers
Currently open trials in the same condition.
- NCT07170293 — Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid Tumors · Phase 2 · recruiting
- NCT07479667 — An Antibody-armored Dendritic Cell in Patients With Solid Tumors · Phase 1 · recruiting
- NCT07371663 — An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07167381 — xDRIVE for Florida-based Cancer Patients · NA · recruiting
- NCT07058948 — Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors · Phase 2 · recruiting
Other Centre de recherche du Centre hospitalier universitaire de Sherbrooke trials
Trials by the same sponsor.
- NCT06732336 — HER2-PET Imaging in HER2-low Breast Cancers · Phase 1, PHASE2 · recruiting
- NCT05202938 — eMESH Struct. 2022-23 · unknown
- NCT04050189 — Validation of the In-utero Transmission of Probiotics · Phase 2 · completed
- NCT05214820 — 68Ga-PSMA PET Imaging of Upper Metastatic Gastric Cancers to Determine Eligibility to Endoradiotherapy · Phase 2 · recruiting
- NCT04559217 — 68Ga-DOTATATE Neuroblastoma Imaging Pilot · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05228106 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre de recherche du Centre hospitalier universitaire de Sherbrooke
- Last refreshed: 7 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05228106.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing